European Innovation Council

Brevel is a company that specializes in innovative cultivation technology for microalgae, aimed at producing sustainable and high-quality products for various emerging markets. Utilizing advanced indoor systems that are sterile and fully automated, Brevel's method employs high-intensity internal illumination, resulting in significant cost reductions of over 90% and yield increases of up to 200 times compared to traditional methods. This breakthrough technology positions Brevel to capitalize on the growing demand for microalgae-derived products in sectors such as food, materials, chemicals, pharmaceuticals, and energy, providing an alternative protein source suitable for mass production.

PrecisionLife is a company focused on advancing precision medicine by leveraging its proprietary artificial intelligence platform to enhance the understanding of chronic diseases. It specializes in patient stratification, which allows for the identification of novel subgroups within patient populations, thereby generating insights that inform the discovery of new drug targets and drug repositioning candidates. By utilizing unique and patentable biomarkers, PrecisionLife connects patients with specific disease sub-groups and potential therapies, ultimately aiming to create personalized treatment alternatives. The company’s innovative approach not only drives advancements in biopharmaceuticals but also seeks to improve patient outcomes, enabling individuals to lead longer and healthier lives.

Stablepharma Ltd is a biotechnology company based in Bath, United Kingdom, focused on developing innovative processes for vaccine stabilization. Its technology platform, StablevaX™, transforms existing approved vaccines, therapeutics, and diagnostics into thermostable products that do not require refrigeration, addressing significant challenges in cold chain logistics. By enabling pre-dosed and stable vaccine delivery, Stablepharma aims to eliminate waste and reduce costs in the distribution of medical products. The company has identified up to 60 vaccine candidates suitable for its technology and collaborates actively with global vaccine manufacturers, academic institutions, and non-governmental organizations to advance its pipeline of thermostable solutions. Established in 2012, Stablepharma is dedicated to improving access to vaccines for children and adults, while also contributing to reduced carbon dioxide emissions in the healthcare sector.

AlzeCure Pharma AB is a pharmaceutical company based in Huddinge, Sweden, that specializes in developing drug therapies aimed at treating diseases affecting the central nervous system, with a particular emphasis on Alzheimer's disease. Established in 2012, the company is advancing multiple drug candidates through its research platforms, NeuroRestore and Alzstatin, among others. Current projects include ACD855, which is undergoing Phase I clinical trials for sleep disruptions, traumatic brain injuries, and Alzheimer's disease, along with several other candidates targeting Alzheimer's: ACD856, ACD679, and ACD680. Additionally, AlzeCure is developing ACD857 for eye and ear conditions, and VR1 for neuropathic pain, alongside TrkA-NAM for osteoarthritic pain. Through its focused research initiatives, AlzeCure Pharma aims to address significant unmet medical needs in neurodegenerative diseases.

QDI Systems B.V. is a startup based in Groningen, the Netherlands, focused on developing advanced imaging devices for medical applications using quantum dot technology. The company specializes in creating X-ray sensors that deliver high-contrast and high-resolution imaging, particularly for mammography, while also reducing radiation exposure for patients. QDI Systems aims to provide user-friendly quantum dot materials accompanied by comprehensive instructions for constructing high-performance imaging devices. By leveraging innovative technology, the company enhances the precision of medical imaging, enabling healthcare professionals to obtain critical diagnostic information efficiently and safely.

QDI Systems B.V. is a startup based in Groningen, the Netherlands, focused on developing advanced imaging devices for medical applications using quantum dot technology. The company specializes in creating X-ray sensors that deliver high-contrast and high-resolution imaging, particularly for mammography, while also reducing radiation exposure for patients. QDI Systems aims to provide user-friendly quantum dot materials accompanied by comprehensive instructions for constructing high-performance imaging devices. By leveraging innovative technology, the company enhances the precision of medical imaging, enabling healthcare professionals to obtain critical diagnostic information efficiently and safely.

Elicera Therapeutics is a clinical-stage immuno-oncology company based in Sweden that focuses on developing innovative cell and gene therapies to treat cancer. The company’s portfolio includes four drug candidates: two oncolytic virus therapies, ELC-100 and ELC-201, and two CAR T-cell treatments, ELC-301 and ELC-401. Additionally, Elicera has developed a universal CAR T-cell technology platform named iTANK (ELC-001), designed to enhance the efficacy of CAR T-cell therapies by enabling a multi-targeted approach against solid tumors. With its commitment to advancing immune-based cancer treatments, Elicera Therapeutics aims to improve outcomes for patients facing various forms of cancer.

Aplagon is a biopharmaceutical company focused on the development of innovative antithrombotic compounds aimed at addressing unmet medical needs in patients experiencing complications from vascular interventions. The company specializes in creating biological mimetics of heparin proteoglycan, which are designed to effectively manage thrombotic occlusions and ischemic reperfusion injuries associated with vascular injuries. By prioritizing safety and efficacy, Aplagon seeks to deliver antithrombotic therapies that offer significant advantages over existing treatments, ultimately improving patient outcomes in challenging medical scenarios.

TENSIVE s.r.l. is a biomedical company based in Milan, Italy, founded in 2012. It specializes in the development of innovative prostheses for natural breast reconstruction and augmentation. The company's products utilize biodegradable synthetic biomaterials and feature an internal micro-architecture that mimics blood vessel structures. These vascularized prostheses aim to enhance the quality of life for patients undergoing treatment for breast cancer, offering a solution that reduces the need for recurrent and costly surgical interventions. Through its focus on advanced biomaterials and design, TENSIVE seeks to provide effective and sustainable options for breast reconstruction.

Hervolution Therapeutics focuses on developing first-in-class immunotherapies to combat tumors from within. The company leverages Human Endogenous Retroviral proteins (HERVs) to create rationally designed immune therapeutics targeting the dark genome. Hervolution Therapeutics aims to address hidden enemies within the human body by pioneering innovative biotechnology solutions.

FibriTech specializes in the development of advanced 3D fibrous network materials with a range of applications across various industries. The company focuses on creating innovative technologies that provide sustainable alternatives to conventional materials such as Styrofoam, rock wool, and foamed plastics. Their offerings include products and services in agritech, packaging, filters, insulators, ecomaterials, hydroponics, and biocomposites, emphasizing lightness and strength in their biomaterials. FibriTech's solutions aim to meet the growing demand for environmentally friendly materials, supporting clients in reducing their reliance on problematic spatial materials.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

Sequentia Biotech, founded in 2013 by Walter Sanseverino and Riccardo Aiese Cigliano, is a bioinformatics company based at the UAB Research Park. The company specializes in transforming genomic data into actionable knowledge for various sectors including academic research, plant and animal breeding, and biomedicine. Sequentia serves a diverse client base of over 30 public and private research centers, companies, and hospitals, participating in more than 160 R&D projects. The company offers cloud software, custom software, and bioinformatics consulting services, with notable contributions such as two open-source biodata banks and an award-winning R&D line called Tricopharming, established in 2014. Sanseverino and Aiese have published over 40 scientific articles in high-impact journals, underscoring the company's expertise in omics sciences.

Oryl Photonics specializes in developing laboratory instruments for pharmaceutical and biotech companies. Their core product provides a simple, reliable, and cost-effective method for measuring solubility, contributing to accelerated drug development and improved medicine. The company's unique technology preserves valuable substances during testing, offering a solubility measurement service that empowers researchers to make data-driven decisions and expedite product development.

Onego Bio is a biotechnology company focused on producing animal-free egg white protein through precision fermentation. Their flagship product, Bioalbumen, offers a sustainable alternative to traditional egg proteins, boasting identical taste and nutritional profiles while providing superior functional properties and a significantly reduced environmental footprint. By employing commercially proven technology, Onego Bio meets the growing demand for stable and sustainable functional ingredients within the food industry. The company has gained recognition as a leader in innovation, winning Fast Company’s 2023 World Changing Ideas award. Additionally, Onego Bio is actively involved in the industry as a co-founder of the Precision Fermentation Alliance and Food Fermentation Europe, further establishing its commitment to advancing sustainable food solutions.

MediWound Ltd. is an integrated biopharmaceutical company based in Yavne, Israel, that specializes in developing, manufacturing, and commercializing innovative therapeutic products for severe burns and chronic wounds. Founded in 2000, the company is known for its flagship product, NexoBrid, which is an FDA-approved biopharmaceutical designed for the removal of eschar in adults with deep partial- and full-thickness thermal burns, offering a less invasive alternative to surgical interventions. MediWound also advances other product candidates, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic and hard-to-heal wounds, and MWPC003 for connective tissue disorders. The company aims to address significant unmet medical needs in these areas and improve patient outcomes.

MediWound Ltd. is an integrated biopharmaceutical company based in Yavne, Israel, that specializes in developing, manufacturing, and commercializing innovative therapeutic products for severe burns and chronic wounds. Founded in 2000, the company is known for its flagship product, NexoBrid, which is an FDA-approved biopharmaceutical designed for the removal of eschar in adults with deep partial- and full-thickness thermal burns, offering a less invasive alternative to surgical interventions. MediWound also advances other product candidates, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic and hard-to-heal wounds, and MWPC003 for connective tissue disorders. The company aims to address significant unmet medical needs in these areas and improve patient outcomes.

iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.

ProFuse Technology is a developer of advanced cultured meat production technology aimed at transforming traditional meat production methods. The company focuses on enhancing the efficiency of meat production by significantly reducing production time, improving the quality of the meat, and increasing overall yields. By accelerating muscle fiber growth, ProFuse's innovative technology enables meat producers to optimize their processes, leading to cost reductions and increased production capacity. This approach positions ProFuse Technology at the forefront of the cultured meat industry, addressing the growing demand for sustainable and high-quality meat alternatives.

BOYDSense is a medical device company founded in 2015 and headquartered in South San Francisco, California. The company specializes in developing non-invasive and affordable tools for measuring critical biomarkers through exhaled breath. BOYDSense focuses on breath-based metabolomics, which involves capturing, identifying, and quantifying volatile organic compound (VOC) biomarker patterns found in human breath. This innovative approach enables medical professionals to simplify the monitoring, screening, and risk stratification of chronic diseases, facilitating more effective diagnosis and ongoing management of these conditions.

RS Research is a clinical-stage biotechnology company based in Istanbul, Turkey, focused on developing innovative nanomedicines for cancer treatment. Founded in 2015, the company has established a proprietary drug delivery platform known as Sagitta®, which enhances the therapeutic index of its drug candidates. RS Research’s pipeline includes multiple proprietary programs at various stages of preclinical and clinical development, with its lead candidate, RS-0139, currently undergoing Phase I clinical trials in oncology patients. The company also offers a range of services, including preclinical absorption and metabolism assessments, bioanalytical testing, and patent consulting. Additionally, RS Research operates a GMP-certified production facility for the manufacture of clinical batch drug candidates and actively engages in co-development projects with international partners.

Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

FreezeM is a company focused on advancing the use of insects as a sustainable protein source for the animal feed industry. Recognizing the potential of insects to address the growing demand for alternative protein, FreezeM develops innovative preservation technologies that facilitate large-scale freezing of insect species. This process aims to create a reliable supply of ready-to-use suspended neonates and frozen eggs, akin to agricultural seed production, which can overcome challenges related to availability, cost, and regulatory constraints. By establishing global stocks of beneficial insects, FreezeM supports various applications, including protein for animal feed, biological pest control, and species preservation, ultimately contributing to a more sustainable food system.

Palobiofarma is a Spanish biotechnology company based in Barcelona’s Science Park, dedicated to discovering and developing innovative drugs that target adenosine receptors. The company aims to be the first European entity to bring an adenosine modulator to market, focusing on the treatment of diseases such as advanced prostate cancer. Through its expertise in medicinal chemistry and in vitro pharmacology, Palobiofarma is committed to advancing the understanding of adenosine's role in disease and enabling healthcare professionals to improve patient outcomes through novel therapeutic options.

NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, focused on the identification and development of therapeutic molecules aimed at treating various forms of cancer. Established in 2008, the company specializes in targeting dependence receptors, which are trans-membrane proteins that play a crucial role in cellular signaling and tumor control. NETRIS Pharma conducts both in vitro and in vivo research, as well as preclinical practices, to manufacture drugs specifically for the treatment of breast cancer, lung cancer, glioblastoma, and neuroblastoma. Through its innovative approach, the company aims to advance cancer therapies and contribute to improved patient outcomes in the pharmaceutical industry.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing innovative treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating novel antibacterial resistance-breakers, including stand-alone inhibitors of bacterial metalloenzymes. These inhibitors are designed to be combined with existing antibiotics, such as carbapenems, to restore their efficacy against the most challenging pathogens responsible for life-threatening infections, including carbapenem-resistant nosocomial pneumonia. Antabio aims to address significant unmet medical needs in the treatment of drug-resistant infections, ultimately providing healthcare professionals with effective medicinal products to combat these critical health challenges. The company has been recognized for its work, receiving a Wellcome Trust Seeding Drug Discovery Award.

RespiQ is a healthtech startup focused on developing portable, non-invasive breath analysis technology for the early detection and management of respiratory diseases. The company employs advanced emission spectroscopy and artificial intelligence to identify volatile organic compounds in breath, facilitating real-time detection of conditions such as COPD exacerbations. RespiQ emphasizes affordability, portability, and user-friendliness to democratize access to advanced diagnostics, thereby enhancing patient outcomes and reducing healthcare costs. In addition to its primary focus on respiratory diseases, RespiQ's versatile platform technology has potential applications for conditions such as asthma, lung cancer, and infectious diseases. The company also offers an intuitive app that provides personalized health insights, allowing users to monitor changes in their health and make informed dietary choices, ultimately empowering individuals to improve their overall well-being.

NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects.

ResoTher Pharma is a privately held biotechnology company based in Copenhagen, Denmark. The company specializes in developing peptide-based drugs derived from Annexin A1, an endogenous immunomodulator. These drugs are designed as resolution therapies for diseases where neutrophil-driven inflammation is a key pathological factor. ResoTher Pharma's primary focus is on addressing cardiovascular and inflammatory disorders that have significant unmet medical needs. Their patented peptide drugs target a G-protein coupled receptor expressed on leukocytes, aiming to mimic the body's natural response to resolving inflammation and promoting tissue repair.

SolasCure Limited is a biotechnology company based in Wales, United Kingdom, focused on advancing treatment options for patients with chronic wounds. Founded in 2017, the company is developing Aurase, a hydrogel designed to enhance wound bed preparation through the application of a recombinant enzyme derived from maggots. This innovative approach aims to facilitate wound debridement, a crucial therapeutic procedure that removes dead, damaged, or infected tissue, thereby accelerating the healing process. By leveraging biomimicry and evidence-based medicine, SolasCure seeks to improve patient outcomes across various healthcare settings.

FarmInsect GmbH, established in 2019 and headquartered in Bergkirchen, Germany, specializes in automated insect breeding systems. The company develops machines and IoT solutions that enable regional farmers to rear insects on-site for use as animal feed, primarily for chickens, pigs, and fish. This sustainable approach aims to replace imported soy or fishmeal with locally produced protein feed, thereby enhancing the efficiency of animal husbandry while reducing environmental impact.

Cellevate AB, founded in 2014 and based in Lund, Sweden, is an innovative biotech company specializing in the development of advanced cell culture systems. The company's flagship product, 3D NanoMatrix, consists of nanofiber scaffolds designed to serve as realistic in-vitro models for scientific research and development across various industries including automotive, construction, defense, electronics, energy, environment, and healthcare. These nanofiber scaffolds are created through a patented manufacturing process that produces porous and consistent networks of nanofibers, enhancing the realism of cell culture systems used in upstream bioprocessing.

Lithos Crop Protect is a producer of non-toxic, biological, and highly effective crop protection products and solutions intended to help crop growers control pests and protect agriculture. They are developing an active ingredient that can make a significant contribution to preventing the spread of the corn rootworm in rapidly advancing products for the agriculture industry.

Epigene Labs SAS is a biotechnology firm focused on enhancing precision oncology through its advanced technology platform that utilizes artificial intelligence. Founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, the company addresses the significant challenges of aggregating, analyzing, and visualizing extensive genomic data in cancer research. By integrating proprietary data from partners with publicly available datasets, Epigene Labs provides medical researchers with actionable insights and user-friendly analytics. The company collaborates with leading cancer centers and prominent biotech firms to develop intelligence-augmenting services that support drug discovery and research in precision oncology. Its innovative approach aims to transform genomic data into effective strategies for targeted cancer therapies.

RUBYnanomed provides non-invasive monitoring of cancer progression. They enable the analysis of their phenotypic, genetic, and functional characteristics, facilitating unprecedentedly frequent monitoring of cancer progression in a minimally invasive, cost-efficient way. They enable oncologists to detect and analyze the evolution of cancer subtypes and therapeutic resistance mechanisms in each patient, providing personalized therapy insights to treat their patients.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels using a proprietary polymer-based technology. Xeltis' RestoreX platform enables the body's natural healing system to develop tissue that replaces the implant, forming a new functional valve or vessel. The company's restorative devices include implantable small diameter blood vessels for hemodialysis and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. Xeltis has raised funding from various venture capital firms and European institutions, including a €30 million round in 2021.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

Genomika Lietuva is a business that provides cutting-edge, perceptive, and meticulously optimized solutions for the biomedical sciences. It creates DNA storage technologies that allow for high-density storage of significant amounts of information in a remarkably tiny area.

Pulse is a platform for furthering our understanding of bioprinting and its applications in space exploration and medicine.

Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.

Elgan Pharma is a biotechnology company specializing in neonatology, primarily focused on addressing the medical challenges faced by premature infants. The company develops innovative therapies using nanotechnology aimed at preventing visual impairment, a significant concern for preterm babies. By targeting the multifactorial causes of visual disabilities, Elgan Pharma enables healthcare professionals to improve visual outcomes and reduce the risk of long-term disabilities in this vulnerable population. Through its advancements in late-stage development, the company is committed to enhancing the quality of care for premature infants and addressing critical developmental difficulties associated with their early birth.

ADmit Therapeutics, S.L. is a biotechnology company based in Begues, Spain, focused on developing diagnostic tests for the early detection of Alzheimer’s disease. Founded in 2017, the company utilizes epigenetic analysis of blood samples to identify a series of mitochondrial biomarkers, which are unrelated to traditional markers such as ß-amyloid or tau. By employing next-generation sequencing to analyze methylcytosines in mitochondrial DNA, ADmit Therapeutics provides medical practitioners with a simplified method for detecting early-stage Alzheimer’s disease. This innovative approach not only aids in diagnosis but also supports pharmaceutical companies in the accelerated identification of potential curative drugs.

Plasmacure, headquartered in Eindhoven, Netherlands, is a medical technology company focused on developing innovative solutions for chronic wound healing, with a particular emphasis on diabetic foot wounds. The company's core product is a patented cold plasma solution designed to kill bacteria, stimulate cell proliferation, and improve microcirculation, thereby reducing the risk of amputation and enhancing patients' quality of life.

Cellbox Solutions is a technology company that specializes in innovative logistic solutions for the global BioMed industry. It has developed a carbon dioxide incubator designed for the storage, isolation, handling, and analysis of biological materials. This incubator offers essential logistic services and ensures the proper handling of living cells, facilitating their storage, reproduction, transportation, and analysis. By enabling the transportation of living cells via various methods, including road, rail, and air, Cellbox Solutions supports healthcare providers in their efforts to deliver the latest therapies to patients.

InProTher Aps is a biotechnology company based in Copenhagen, Denmark, focusing on the development of innovative vaccine technologies and candidates within the field of immunotherapy. Established in 2011, the company is dedicated to creating the first adaptive immune therapy that targets immunosuppressive genes associated with ancient retroviruses. InProTher is also engaged in the development of products aimed at combating HIV, papilloma viruses, and various forms of cancer. Through its research and development efforts, InProTher seeks to advance treatment options in the evolving landscape of immunotherapy.

Scandinavian Real Heart AB is a medical technology company focused on creating advanced artificial heart solutions. The company's flagship product, the Total Artificial Heart (TAH), aims to closely replicate the natural pumping function, pressure ratios, and pulse of a healthy heart. Designed primarily as a transitional solution, the TAH is intended for patients awaiting heart transplants, offering enhanced functionality compared to existing devices in the market. Through its innovative approach, Scandinavian Real Heart seeks to address the critical needs of individuals facing severe heart conditions and improve their chances of survival while awaiting surgical intervention.

Arthex Biotech S.L. is a biotechnology company founded in 2019 and based in Paterna, Spain. It specializes in the development of antisense RNA treatments specifically aimed at addressing genetic diseases and disorders where microRNAs play a significant role. As a spin-off from the University of Valencia, Arthex Biotech leverages a strong foundation in drug discovery and has a team comprising experts with extensive experience in neuromuscular diseases. The company focuses on creating innovative therapies for conditions with unmet medical needs, providing new treatment options for patients suffering from rare genetic diseases and other high-need medical issues. With guidance from esteemed scientific and clinical advisors, Arthex Biotech is committed to advancing its product development to improve patient outcomes.

3DSecret is developing cutting-edge technologies to uncover the stochastic patterns behind metastasis in order to predict the course of cancer.

Abbelight is a company specializing in super-resolution microscopy, specifically through its innovative single molecule localization microscopy technology. This technology integrates consumables, hardware, and software to deliver state-of-the-art solutions for biological research, enhancing the ability to observe biological samples with superior resolution. By focusing on simplifying the use of advanced microscopy techniques, Abbelight aims to make these cutting-edge tools accessible to a wide range of laboratories without compromising performance. The company supports scientists throughout their research process, from sample preparation to result analysis, by offering expertise in chemistry, computer science, and optical instrumentation. Abbelight's commitment is to empower researchers in biology, pharmacology, and environmental science with reliable and advanced imaging capabilities.

Norbite is a biotechnology research firm that specializes in converting plastic waste into sustainable products through an innovative insect-based biorefinery process. The company's technology enables the production of sustainable goods by utilizing larvae that are bio-refined to extract proteins suitable for food and animal feed. By focusing on the transformation of plastic waste, Norbite aims to provide environmentally friendly solutions while addressing the growing concerns of waste management and sustainability. Through its unique approach, the firm contributes to the development of sustainable products and services that benefit both clients and the environment.

Inobiostar focuses on research and experimental development services.

Smart Immune is a clinical-stage biotechnology company dedicated to advancing hematopoietic stem cell-based biotherapies aimed at improving the prognosis and quality of life for patients with severe diseases. The company's primary focus is on its innovative cell therapy program that utilizes T cell progenitors, known as ProTcells, which are designed to facilitate a rapid and safe immune recovery following transplantation. This program is complemented by integrative developments in targeted conditioning, gene therapy, and genome editing, allowing for the creation of next-generation treatments. Smart Immune's approach aims to provide effective allogeneic T-cell therapies for patients suffering from life-threatening conditions, particularly hematological malignancies and primary immune deficiencies.

Samplix is a biotechnology company based in Herlev, Denmark, that specializes in advanced sample preparation for single DNA and RNA molecules. The company has developed the proprietary Xdrop™ technology, which utilizes a unique "water-oil-water" droplet formation to create millions of reaction chambers for handling individual DNA molecules. This innovative technology allows for targeted enrichment of large DNA fragments, addressing the limitations of existing multi-molecule preparation methods. By enabling precise and sensitive sample preparation, Samplix empowers researchers to conduct more informed studies, facilitating the sequencing of genetic regions critical for understanding virus integration and minimizing unintended CRISPR edits. The Xdrop™ system includes both the instrumentation and consumables needed for effective single-molecule analysis, thereby enhancing the ease of use and efficiency in molecular research.

Samplix is a biotechnology company based in Herlev, Denmark, that specializes in advanced sample preparation for single DNA and RNA molecules. The company has developed the proprietary Xdrop™ technology, which utilizes a unique "water-oil-water" droplet formation to create millions of reaction chambers for handling individual DNA molecules. This innovative technology allows for targeted enrichment of large DNA fragments, addressing the limitations of existing multi-molecule preparation methods. By enabling precise and sensitive sample preparation, Samplix empowers researchers to conduct more informed studies, facilitating the sequencing of genetic regions critical for understanding virus integration and minimizing unintended CRISPR edits. The Xdrop™ system includes both the instrumentation and consumables needed for effective single-molecule analysis, thereby enhancing the ease of use and efficiency in molecular research.

Smart Immune is a clinical-stage biotechnology company dedicated to advancing hematopoietic stem cell-based biotherapies aimed at improving the prognosis and quality of life for patients with severe diseases. The company's primary focus is on its innovative cell therapy program that utilizes T cell progenitors, known as ProTcells, which are designed to facilitate a rapid and safe immune recovery following transplantation. This program is complemented by integrative developments in targeted conditioning, gene therapy, and genome editing, allowing for the creation of next-generation treatments. Smart Immune's approach aims to provide effective allogeneic T-cell therapies for patients suffering from life-threatening conditions, particularly hematological malignancies and primary immune deficiencies.

Nemysis Limited is a specialty pharmaceutical company based in Dublin, Ireland, founded in 2005. The company focuses on addressing unmet needs in nutritional disorders and deficiencies through a staged approach to product development. Nemysis manufactures food supplements, medical matrix products, and prescription items, targeting the same conditions across different market segments. Among its innovative offerings are a gastric and trypsin-resistant glutenous product for oral enzymatic therapy aimed at celiac disease patients, as well as an iron supplement designed to minimize gastrointestinal side effects associated with iron supplementation. Additionally, the company is developing a glutenous medical device that effectively destroys gluten, helping to prevent symptoms in individuals with celiac disease and non-celiac gluten sensitivity.

Inbiome is a trailblazing company in molecular diagnostics, specializing in proprietary molecular culture technology. This innovation enables swift bacterial testing and microbiome analysis, significantly expediting the process compared to traditional methods. The company's primary mission is to advance clinical microbiology by focusing on microbial detection and product development, thereby guiding clinicians towards more accurate and timely diagnoses. By offering advanced molecular technology for microbiome analysis, Inbiome aids in enhancing the understanding of bacteria in the human body, facilitating correct treatments, and mitigating unnecessary complications, costs, and anti-microbial resistance.

Molecular Attraction is a research and development firm focused on creating innovative solutions for vector-borne disease control and eradication. The company specializes in identifying biological compounds that can influence the behavior of various vector organisms, including mosquitoes, ticks, flies, and rodents. By utilizing sustainable technology and chemical blends, Molecular Attraction aims to provide effective, long-lasting, and low-maintenance pest control solutions. Their approach is designed to enhance the efficacy of vector-borne disease management while prioritizing environmental sustainability and cost-effectiveness within the pest control industry.

IDloop specializes in biometric technology, focusing on contactless fingerprint sensor solutions tailored for business and government sectors. The company employs advanced 3D imaging, artificial intelligence, and embedded technology to deliver secure, high-quality multi-finger image capture. By facilitating large-scale biometric data acquisition, IDloop's solutions significantly reduce false acceptance rates, thereby enhancing overall security for its clients.

Valo Therapeutics is an immunotherapy company focused on developing antigen-coated oncolytic viruses as therapeutic vaccines for cancer treatment. Founded in 2016 and based in Oxford, United Kingdom, with an additional office in Helsinki, Finland, the company utilizes its innovative Valo Tx platform, which includes PeptiCRAd, an engineered human oncolytic adenovirus. This platform is designed to induce systemic anti-tumor T cell responses by transforming oncolytic adenoviruses into targeted, tissue-specific cancer vaccines without requiring the production of multiple genetically modified viruses. Valo Therapeutics is also advancing other neoantigen strategies, including PeptiENV, in collaboration with Professor Vincenzo Cerullo from the University of Helsinki, to enhance therapeutic responses against various cancer types.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.

Iris.ai is a company that offers an AI-driven science assistant designed to enhance research and development efforts in various sectors, including corporate and academic environments. Its RSpace solution features advanced capabilities such as smart search, a variety of filters, reading list analysis, auto-generated summaries, and autonomous data extraction and systematization. By leveraging natural language processing algorithms, Iris.ai aims to improve the efficiency and innovation of corporate R&D by providing tools that facilitate the tracking of factuality in scientific texts. This platform empowers research teams to conduct secondary scientific research more effectively, enabling them to access and analyze the latest scientific insights that exceed traditional human capabilities.

N2 Applied is a Norwegian technology company focused on enabling farmers to produce their own sustainable fertilizer through an innovative process that utilizes slurry, air, and electricity. The company is in the pre-commercial phase and has developed a technology that allows for the local production of nitrogen-rich fertilizer from liquid organic substrates, such as livestock manure. By integrating nitrogen from the atmosphere into these substrates, N2 Applied's solution not only enhances the nitrogen content but also mitigates ammonia loss and reduces greenhouse gas emissions. The company operates its head office in Oslo/Asker and maintains a test center in Svene, with additional branches in Wageningen and York. N2 Applied's scalable process aims to eliminate the lengthy and costly supply chains associated with traditional fertilizer production, facilitating a more circular farming system. This approach not only provides farmers with cost-effective and environmentally friendly fertilizer but also contributes to on-farm reductions in methane and ammonia emissions.

Iris.ai is a company that offers an AI-driven science assistant designed to enhance research and development efforts in various sectors, including corporate and academic environments. Its RSpace solution features advanced capabilities such as smart search, a variety of filters, reading list analysis, auto-generated summaries, and autonomous data extraction and systematization. By leveraging natural language processing algorithms, Iris.ai aims to improve the efficiency and innovation of corporate R&D by providing tools that facilitate the tracking of factuality in scientific texts. This platform empowers research teams to conduct secondary scientific research more effectively, enabling them to access and analyze the latest scientific insights that exceed traditional human capabilities.

iLoF, or Intelligent Lab on Fiber, is a technology company specializing in the integration of photonics and artificial intelligence to enhance drug discovery and development. The company has developed a patented system that identifies and captures unique features of gold-standard biomarkers, creating a cloud-based digital library of these biological profiles. This platform allows for the collection of extensive data, which facilitates personalized medicine by enabling healthcare companies to conduct more efficient and patient-centric clinical trials. By employing a multidisciplinary approach that involves physicists, biologists, and data scientists, iLoF aims to accelerate the development of tailored treatments, ultimately improving patient outcomes and reducing the costs associated with drug development.

Arctic Therapeutics is a drug discovery and development company that focuses on identifying the genetic underpinnings of both rare and common diseases. Utilizing bioinformatic approaches and artificial intelligence, the company aims to mitigate the risks associated with traditional drug development while significantly reducing the costs and time required to bring effective treatments to patients. With over 20 years of expertise in international genomics research, Arctic Therapeutics employs an innovative methodology in its drug development efforts. Collaborating closely with the Center for Applied Genomics at the Children's Hospital of Philadelphia, the company is actively involved in repurposing and developing breakthrough medical treatments. Notably, Arctic Therapeutics is working on a drug candidate for Alzheimer’s disease that has the potential to become the first cure for dementia, addressing both treatment and prevention. The company was inspired by Dr. Hakon Hakonarson, a prominent figure in applied genomics, whose work has been recognized as pioneering in the field of genetic research and therapeutic development.

Arctic Therapeutics is a drug discovery and development company that focuses on identifying the genetic underpinnings of both rare and common diseases. Utilizing bioinformatic approaches and artificial intelligence, the company aims to mitigate the risks associated with traditional drug development while significantly reducing the costs and time required to bring effective treatments to patients. With over 20 years of expertise in international genomics research, Arctic Therapeutics employs an innovative methodology in its drug development efforts. Collaborating closely with the Center for Applied Genomics at the Children's Hospital of Philadelphia, the company is actively involved in repurposing and developing breakthrough medical treatments. Notably, Arctic Therapeutics is working on a drug candidate for Alzheimer’s disease that has the potential to become the first cure for dementia, addressing both treatment and prevention. The company was inspired by Dr. Hakon Hakonarson, a prominent figure in applied genomics, whose work has been recognized as pioneering in the field of genetic research and therapeutic development.

FreezeM is a company focused on advancing the use of insects as a sustainable protein source for the animal feed industry. Recognizing the potential of insects to address the growing demand for alternative protein, FreezeM develops innovative preservation technologies that facilitate large-scale freezing of insect species. This process aims to create a reliable supply of ready-to-use suspended neonates and frozen eggs, akin to agricultural seed production, which can overcome challenges related to availability, cost, and regulatory constraints. By establishing global stocks of beneficial insects, FreezeM supports various applications, including protein for animal feed, biological pest control, and species preservation, ultimately contributing to a more sustainable food system.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.

iThera Medical is a biotechnology company founded in 2010 as a spin-off from the Helmholtz Zentrum Muenchen, specializing in photonic molecular imaging technology. The company focuses on the development of its proprietary multispectral optoacoustic tomography (MSOT) technology, which offers real-time visualization of anatomical, functional, and molecular information in living tissues. This innovative imaging solution enhances the ability of healthcare professionals to detect tumors and inflammatory diseases non-invasively, thereby facilitating preclinical and clinical trials. By advancing its technology, iThera Medical aims to improve diagnostic capabilities and patient outcomes in the medical field.

Resistell AG is a Swiss company founded in 2018, based in Muttenz, specializing in the development and marketing of innovative diagnostic devices for antibiotic susceptibility testing. The company's platform employs advanced nanomotion technology to detect the movement of living bacterial cells, allowing for the rapid identification of bacterial resistance to antibiotics. This method serves as an alternative to traditional culture-based antibiograms, enabling healthcare providers to administer appropriate antibiotics in a timely manner, ultimately improving patient outcomes.

iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.

iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.

Odd.Bot is a technology company specializing in the development and manufacture of autonomous farming robots. Their flagship product, the Maverick robot, is designed to eliminate weeds in crops like carrots and onions without the use of chemicals. Operating around the clock, the robot effectively identifies and removes weeds in dense crops, promoting environmentally friendly agriculture.

Newronika is a company dedicated to restoring brain and body functions through innovative neuro-modulation technologies. It translates extensive expertise in biosignal decoding into clinical applications aimed at enhancing treatments, health, and overall wellness. By utilizing a therapeutic device that employs a retro-activity system, Newronika records brain activity and modulates neuro-stimulation to analyze and interpret bio-signals. This technology ensures that patients receive the appropriate stimulation at critical moments, enabling them to engage in normal daily activities and improve their quality of life. Founded as a spin-off from two prominent Italian research institutions, the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Hospital and the University of Milan, Newronika prides itself on a multidisciplinary team of scientists specializing in various fields, including neurophysiology, neurology, biomedical engineering, neuropsychology, bioinformatics, and biotechnologies.

ELEM Biotech SL is a biomedical software company based in Barcelona, Spain, that specializes in creating virtual human models through advanced mathematical modeling and cloud computing. Founded in 2018 by researchers from the Barcelona Supercomputing Center, ELEM has developed a suite of simulation tools known as Alya Red. This platform operates on a Software-as-a-Service model and is designed for the medical device and pharmaceutical industries. Alya Red allows for the simulation of cardiovascular and respiratory systems on virtual patients, utilizing high-performance computing, computational biomechanics, and data analysis. These virtual avatars enable biomedical companies and healthcare professionals to enhance diagnostics, plan treatments, optimize drug delivery, and improve medical devices.

FOx Biosystems is a biotechnology company focused on enhancing biomolecular interaction analysis for life science research and industry. Founded in 2017 by Filip Delport and Jeroen Lammertyn, and based in Temse, Oost-Vlaanderen, Belgium, the company specializes in developing custom applications, including probes and devices, to support various research needs. FOx Biosystems employs real-time, label-free analysis technology that offers significant advantages over traditional biomolecular analysis tools, such as ease of use, speed, and cost-effectiveness. This technology enables healthcare companies and researchers to obtain high-quality biomolecular data, including concentration measurements, affinity data, and kinetic data, ultimately aiming to transform the life sciences sector.

Protinhi Therapeutics is a preclinical stage biotechnology company focused on the development of antiviral drugs aimed at combating various viral threats, including dengue, Zika, and COVID-19. The company utilizes proprietary technology and compounds to create therapies that inhibit viral proteases, effectively preventing the viruses from replicating. This mechanism allows healthcare providers to better control the spread of these diseases, addressing significant public health challenges.

VIVAN Therapeutics is a company focused on developing personalized cancer therapeutics aimed at revolutionizing cancer care. Utilizing a novel assay technology licensed from the Center for Personalized Cancer Therapeutics at Mt Sinai New York, VIVAN offers a comprehensive genomics-based drug screening service that integrates blockchain technology. The company's approach includes the Personal Discovery Process (PDP), which treats each patient as a unique case by engineering their tumor's genetic complexity into a model using fruit flies, allowing for the evaluation of both FDA-approved cancer and non-cancer drugs. This innovative strategy aims to provide less toxic and more affordable treatment options, enhancing the effectiveness of cancer care through tailored recommendations and the development of new diagnostics and decision support tools.

IDloop specializes in biometric technology, focusing on contactless fingerprint sensor solutions tailored for business and government sectors. The company employs advanced 3D imaging, artificial intelligence, and embedded technology to deliver secure, high-quality multi-finger image capture. By facilitating large-scale biometric data acquisition, IDloop's solutions significantly reduce false acceptance rates, thereby enhancing overall security for its clients.

CorTec is a developer and manufacturer specializing in medical device components and active implantable systems for neuromodulation applications and brain-computer interfaces. With a decade of intensive research and development, the company has created the CorTec Brain Interchange System, a unique platform technology designed to facilitate the development of novel therapies for neurological diseases. This system features laser-structured AirRay electrode arrays that provide a reliable and flexible interface for permanent brain recordings, gently conforming to the brain's curvature. A biocompatible ceramic encapsulation houses an electronics unit that preprocesses data, while a custom-developed microchip amplifies neuronal signals across multiple channels and digitizes them at a high sampling rate. The system operates without a battery, utilizing an inductive power supply to eliminate the need for surgical replacements. Additionally, CorTec supports Medtech companies and startups in neurotechnology by providing components and services related to the Brain Interchange System.

TENSIVE s.r.l. is a biomedical company based in Milan, Italy, founded in 2012. It specializes in the development of innovative prostheses for natural breast reconstruction and augmentation. The company's products utilize biodegradable synthetic biomaterials and feature an internal micro-architecture that mimics blood vessel structures. These vascularized prostheses aim to enhance the quality of life for patients undergoing treatment for breast cancer, offering a solution that reduces the need for recurrent and costly surgical interventions. Through its focus on advanced biomaterials and design, TENSIVE seeks to provide effective and sustainable options for breast reconstruction.

Actome is a biotechnology company that specializes in the development of advanced interactome technology aimed at enhancing life science research and personalized medicine. The firm employs a proprietary method that allows for the detection of single protein molecules and their interaction complexes. This technology translates the status of proteins into DNA barcodes through the use of DNA-labeled antibodies, facilitating detailed molecular biological research. Actome's innovations enable clients to analyze protein quantification, interactions, and post-translational modifications within biological samples, thereby contributing to advancements in pharmaceuticals and tailored therapeutic solutions.

Herantis Pharma is a biotech company focused on addressing unmet clinical needs, particularly in the field of neurodegenerative diseases. The company's primary development program centers on HER-096, a peptidomimetic molecule designed to mimic the biological activity of the neuroprotective CDNF protein. By targeting Parkinson's disease, Herantis Pharma aims to develop disease-modifying therapies that could significantly improve patient outcomes.

Precisis is a medical device company founded in 2004 and headquartered in Heidelberg, Baden-Württemberg, Germany. The company focuses on developing innovative products aimed at treating epilepsy and enhancing patients' quality of life. Its flagship device provides individualized brain stimulation through a surgical procedure that places the device beneath the scalp, precisely targeting the origin of epileptic activity in the brain. This technology allows for the delivery of therapeutic currents to specific areas, enabling effective treatment without direct contact with brain tissue.

Herantis Pharma is a biotech company focused on addressing unmet clinical needs, particularly in the field of neurodegenerative diseases. The company's primary development program centers on HER-096, a peptidomimetic molecule designed to mimic the biological activity of the neuroprotective CDNF protein. By targeting Parkinson's disease, Herantis Pharma aims to develop disease-modifying therapies that could significantly improve patient outcomes.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

Elicit Plant is an agro-biotech company focused on enhancing crops' resilience to water stress and developing innovative phytosterol-based solutions. By utilizing proprietary technology, the company aims to improve plant stress resistance and activate their natural defenses, addressing the global challenges posed by climate change in agriculture. Extensive field trials conducted across three continents have shown that Elicit Plant's biosolutions are effective, providing farmers with consistent and substantial returns on investment. Through its advancements, Elicit Plant seeks to lead the ecological transition in agriculture, ensuring that crops are better equipped to handle water shortages and contribute to sustainable farming practices.

Gate2Brain is an early-stage biotechnology company dedicated to enhancing drug delivery across biological barriers, with a focus on improving treatments for brain diseases. The company's proprietary technology employs peptide-based innovations to facilitate drug transport across barriers like the blood-brain barrier, aiming to increase treatment efficiency and minimize side effects.

Enduro Genetics is a technology provider that specializes in enhancing large-scale fermentations through its proprietary synthetic biology technology. The company focuses on improving the performance of fermentation processes by developing a genetic plugin technology that is free of antibiotic resistance genes. This innovation allows for higher yields by enriching spontaneous high producers within the fermentation population, facilitating the production of complex or cellular inhibit products by addressing strain instability. By maximizing the performance of cells derived from production strains, Enduro aims to bolster the competitiveness of both current and future green bioproduction initiatives.

ABCDx SA is a privately-funded company based in Geneva, Switzerland, founded in 2014 by three experts in the field of brain biomarkers. The founders include two prominent researchers from the Faculty of Medicine at the University of Geneva and the Vall d’Hebron Research Institute, who are recognized for their contributions to biomarker discovery and validation. The third founder brings extensive experience in the diagnostic and pharmaceutical industries. ABCDx specializes in the development and validation of biomarker and biomarker panel tests aimed at enhancing the diagnosis and treatment of brain injuries. The company's offerings are designed to identify and assess patients at risk of severe long-term complications stemming from traumatic injuries, strokes, and post-stroke infections. Through its innovative approach, ABCDx aims to improve patient outcomes in the realm of brain health.

Alvus offers biomethane services. They offer project development, construction, and operation of biogas plants. They assist their customers in every aspect related to a biogas plant, due diligence analysis, business plan verification, site selection, biomass research, choice of power supply plan, selection of the most suitable technology.

Variolytics is a developer of advanced measurement technologies, specializing in mass spectrometry for environmental applications, particularly in sewage treatment plants. The company focuses on measuring all gas components, including greenhouse gases, within aeration tanks. Variolytics offers a range of products including measuring devices, sensor technologies, and monitoring systems that facilitate accurate data collection and process integration. In addition to its innovative measurement solutions, the company conducts process engineering research and development, providing expert advice and implementation services to help businesses optimize their industrial processes. By delivering insights into process dynamics, Variolytics enables companies to make informed decisions and enhance operational efficiency.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. It specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. The company has created the world's first graphene-based brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation. This innovative technology allows for real-time monitoring and adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By utilizing AI-driven solutions, INBRAIN maximizes therapeutic outcomes while minimizing side effects. The company is also expanding its capabilities through strategic partnerships, including collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, to explore applications in peripheral nerve and systemic diseases, advancing the field of neurotechnology and bioelectronics.

Xenikos is a biopharmaceutical company focused on developing innovative immunotherapy treatments aimed at restoring health to patients suffering from serious immune diseases and transplant rejection. The company specializes in creating anti-T-cell antibodies that act as a therapeutic tool to reset the immune system. Once administered, these antibodies specifically target and eliminate activated adult T cells, allowing for improved treatment outcomes in various medical conditions. By harnessing the potential of antibody action, Xenikos aims to provide efficient solutions that can significantly enhance patient recovery and overall well-being.

Novus Diagnostics is focused on developing an innovative diagnostic device aimed at detecting sepsis. This technology allows for the rapid and automated identification of pathogens present in whole blood samples. By providing results in minutes, Novus Diagnostics empowers healthcare providers to initiate effective treatment for sepsis patients quickly and efficiently. The approach not only enhances patient care but also aims to reduce costs associated with sepsis management.

Cherry Biotech is a biomedical technology company specializing in Organ on Chip systems that facilitate drug discovery and personalized medicine. The company focuses on developing microfluidic technology that allows for the culture and simulation of human organs under various physiological and pathological conditions. Cherry Biotech also provides temperature controllers for rapid temperature adjustments and next-generation 3D cell culture technologies. These innovations assist clinicians in accurately recapitulating the human cellular microenvironment, which is crucial for drug development and toxicity assessment.

Arthex Biotech S.L. is a biotechnology company founded in 2019 and based in Paterna, Spain. It specializes in the development of antisense RNA treatments specifically aimed at addressing genetic diseases and disorders where microRNAs play a significant role. As a spin-off from the University of Valencia, Arthex Biotech leverages a strong foundation in drug discovery and has a team comprising experts with extensive experience in neuromuscular diseases. The company focuses on creating innovative therapies for conditions with unmet medical needs, providing new treatment options for patients suffering from rare genetic diseases and other high-need medical issues. With guidance from esteemed scientific and clinical advisors, Arthex Biotech is committed to advancing its product development to improve patient outcomes.

Meletios Therapeutics is a biotechnology company focused on developing antiviral molecules to address both current and emerging diseases. The company specializes in creating antiviral drugs that target the host mechanisms exploited by viruses, thereby providing healthcare institutions with effective treatment options for a variety of pathologies. Through its innovative approach, Meletios Therapeutics aims to fulfill critical medical needs in the realm of antiviral therapeutics.